Search Results Search Sort by RelevanceMost Recent Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Dec 2007 Communicable Disease and Immigration Fears Sonal S. Munsiff, MD Virtual Mentor. 2007;9(12):799-805. doi: 10.1001/virtualmentor.2007.9.12.ccas3-0712. In the Literature Dec 2007 Convincing Physicians to Report Communicable Diseases Sarah Lusk Virtual Mentor. 2007;9(12):811-813. doi: 10.1001/virtualmentor.2007.9.12.jdsc1-0712. State of the Art and Science Dec 2007 Diagnosing and Managing Pulmonary Tuberculosis David Pitrak, MD Virtual Mentor. 2007;9(12):814-818. doi: 10.1001/virtualmentor.2007.9.12.cprl1-0712. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437. Podcast May 2022 Author Interview: “Reimagining Roles of Dietary Supplements in Psychiatric Care” Dr Katherine Wu joins Ethics Talk to discuss her article, coauthored with Dr Erik Messamore: “Reimagining Roles of Dietary Supplements in Psychiatric Care.” AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940. Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777. Pagination Current page 1 Page 2 Next page Next › Last page Last »
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Dec 2007 Communicable Disease and Immigration Fears Sonal S. Munsiff, MD Virtual Mentor. 2007;9(12):799-805. doi: 10.1001/virtualmentor.2007.9.12.ccas3-0712.
In the Literature Dec 2007 Convincing Physicians to Report Communicable Diseases Sarah Lusk Virtual Mentor. 2007;9(12):811-813. doi: 10.1001/virtualmentor.2007.9.12.jdsc1-0712.
State of the Art and Science Dec 2007 Diagnosing and Managing Pulmonary Tuberculosis David Pitrak, MD Virtual Mentor. 2007;9(12):814-818. doi: 10.1001/virtualmentor.2007.9.12.cprl1-0712.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437.
Podcast May 2022 Author Interview: “Reimagining Roles of Dietary Supplements in Psychiatric Care” Dr Katherine Wu joins Ethics Talk to discuss her article, coauthored with Dr Erik Messamore: “Reimagining Roles of Dietary Supplements in Psychiatric Care.”
AMA Code Says Nov 2020 AMA Code of Medical Ethics’ Opinions Related to Risk Management Ethics Scott J. Schweikart, JD, MBE and Deborah M. Eng, MS, MA Ethical dimensions of risk management are illuminated in AMA Code content on discharge planning. AMA J Ethics. 2020;22(11):E940-944. doi: 10.1001/amajethics.2020.940.
Health Law Nov 2020 How Hospital Leaders and Risk Managers Can Nurture Ethics-Driven Lawyering Norine A. McGrath, MD, Evan G. DeRenzo, PhD, John K. Kilcullen, MD, JD, MPH, and Jack Schwartz, JD Hospital lawyers’ practices shape risk management operations, influence clinicians’ morale, and affect patient care. AMA J Ethics. 2020;22(11):E933-939. doi: 10.1001/amajethics.2020.933.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.